Reneo Pharmaceuticals, Inc. SEC Filings

RPHM NASDAQ

Welcome to our dedicated page for Reneo Pharmaceuticals SEC filings (Ticker: RPHM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Parsing a biotech filing packed with trial endpoints and mitochondrial science can feel daunting. Reneo Pharmaceuticals’ latest 10-K alone details multiple clinical studies, cash-burn scenarios, and merger contingencies—information critical to any RPHM investor but buried in technical language.

Stock Titan turns that complexity into clarity. Our AI reads each document the moment it hits EDGAR, providing plain-English summaries and red-flag alerts. Need the Reneo Pharmaceuticals insider trading Form 4 transactions from last night? They’re indexed with context. Looking for the Reneo Pharmaceuticals quarterly earnings report 10-Q filing but want the key R&D spend in seconds? It’s highlighted automatically. From Reneo Pharmaceuticals Form 4 insider transactions real-time to pipeline-moving 8-K updates, you’ll see what matters without sifting through PDFs.

Our coverage spans every form investors ask about. Explore a Reneo Pharmaceuticals annual report 10-K simplified to trace clinical milestones, or open a 10-Q for fresh liquidity analysis. Use AI commentary for Reneo Pharmaceuticals earnings report filing analysis, and tap quick links when understanding Reneo Pharmaceuticals SEC documents with AI. Monitor Reneo Pharmaceuticals executive stock transactions Form 4, evaluate a Reneo Pharmaceuticals proxy statement executive compensation, or read a headline-ready brief on any Reneo Pharmaceuticals 8-K material events explained. Real-time notifications, side-by-side comparisons, and expert notes help professionals track trial progress, cash runway, and insider confidence—so decisions are informed, not rushed.

06/26/2025 04:16 PM

Filing

[8-K] Reneo Pharmaceuticals, Inc. Common Stock Reports Material Event

Rhea-AI Summary

OnKure Therapeutics (Nasdaq:OKUR) filed a routine Form 8-K under Item 7.01 Regulation FD.

On June 26 2025 the company posted an updated corporate presentation on its Investor Relations website and furnished the slide deck as Exhibit 99.1. No new financial data, operational updates or other material events were disclosed.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[Form 4] Reneo Pharmaceuticals, Inc. Common Stock Insider Trading Activity

Rhea-AI Summary

OnKure Therapeutics (OKUR) President, CEO, and Director Nicholas A. Saccomano reported an insider transaction on Form 4 filed June 25, 2025, detailing activity that occurred on June 23, 2025.

Key transaction details:

Disposed of 88 shares of Class A Common Stock at a weighted average price of $2.3842 per share
Transaction was an automatic sale (S) to cover tax withholding obligations related to vesting RSUs
Following the transaction, Saccomano holds 3,594 shares directly

The shares were sold in multiple trades ranging from $2.33 to $2.47 per share. The transaction was executed under the company's 2023 RSU Equity Incentive Plan. The filing was signed by Rogan Nunn via power of attorney.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[Form 4] Reneo Pharmaceuticals, Inc. Common Stock Insider Trading Activity

Rhea-AI Summary

OnKure Therapeutics CFO Jason A. Leverone reported a Form 4 filing for a transaction dated June 23, 2025. The insider sold 303 shares of Class A Common Stock at a weighted average price of $2.3842 per share.

Key details of the transaction:

The sale was automatically executed to cover tax withholding obligations related to vesting RSUs under the company's 2023 RSU Equity Incentive Plan
The transaction was executed through multiple trades with prices ranging from $2.33 to $2.47
Following the transaction, Leverone maintains beneficial ownership of 12,906 shares, some of which are RSUs that represent contingent rights to receive Class A Common Stock

The filing was signed by Rogan Nunn via power of attorney on June 25, 2025. This transaction appears to be a routine tax-related sale rather than a discretionary trading decision by the insider.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of Reneo Pharmaceuticals (RPHM)?

The current stock price of Reneo Pharmaceuticals (RPHM) is $1.82 as of February 7, 2025.

What is the market cap of Reneo Pharmaceuticals (RPHM)?

The market cap of Reneo Pharmaceuticals (RPHM) is approximately 6.1M.

What is the primary focus of Reneo Pharmaceuticals?

Reneo Pharmaceuticals is primarily focused on developing therapies for patients with rare genetic mitochondrial diseases, addressing deficits in cellular metabolism and energy production.

How does Reneo Pharmaceuticals approach drug development?

The company utilizes a rigorous research and development process supported by an experienced team. Their approach emphasizes improvements in mitochondrial function, preservation of muscle functionality, and innovative clinical strategies.

What therapeutic areas does Reneo Pharmaceuticals target?

Reneo targets rare genetic mitochondrial diseases through novel molecular therapies. They also explore avenues in precision oncology, particularly through strategic collaborations and merger discussions.

Who are the patients that could benefit from Reneo's therapies?

Patients suffering from rare mitochondrial disorders, which manifest as deficits in cellular energy production and associated muscle injuries, may benefit from Reneo's therapeutic approaches.

What distinguishes Reneo Pharmaceuticals in the biopharmaceutical industry?

Reneo is distinguished by its specialized focus on mitochondrial dysfunction and its commitment to rigorous scientific methodologies. Their experienced drug development team and integration of precision medicine principles set them apart.

How does Reneo Pharmaceuticals maintain its industry expertise?

They maintain expertise through continuous R&D efforts, collaboration among seasoned professionals, and a disciplined clinical framework. This approach ensures that their strategies remain scientifically sound and cutting-edge.

What recent strategic initiatives has Reneo Pharmaceuticals undertaken?

Reneo has explored strategic alternatives including a merger with a clinical-stage biopharmaceutical company focused on precision oncology. This initiative aligns with their broader goal of expanding their therapeutic portfolio.

How is Reneo Pharmaceuticals addressing challenges in rare disease therapeutics?

By focusing on the underlying mechanisms of mitochondrial dysfunction, Reneo employs a methodical, data-driven approach to develop therapies. Their emphasis on clinical safety, efficacy, and robust research helps address complex challenges in rare disease treatment.